Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis.
Sheehy
Oonagh
O
Catherwood
Mark
M
Pettengell
Ruth
R
Morris
T C Curly
TC
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000077610:Bexarotene; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D006801:Humans; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D017893:Photopheresis; D011241:Prednisone / Q000008:administration & dosage; D016879:Salvage Therapy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D013764:Tetrahydronaphthalenes; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000077610:Bexarotene; D011241:Prednisone